tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ARVN Stock Latest News

Balanced View on Arvinas: Early Promise of ARV-102 Offset by Clinical, Safety, and Competitive Uncertainties Supporting a Hold Rating
RatingsBalanced View on Arvinas: Early Promise of ARV-102 Offset by Clinical, Safety, and Competitive Uncertainties Supporting a Hold Rating
19m ago
ARVN
Arvinas price target raised to $21 from $18 at Citi
PremiumThe Fly
Arvinas price target raised to $21 from $18 at Citi
53m ago
ARVN
ARV-102 Data Strengthens Neurodegeneration Pipeline Prospects, Supporting Higher $16 Target and Buy Rating on Arvinas
PremiumRatings
ARV-102 Data Strengthens Neurodegeneration Pipeline Prospects, Supporting Higher $16 Target and Buy Rating on Arvinas
15h ago
ARVN
Arvinas Reports Positive Phase 1 Data for ARV-102
PremiumCompany Announcements
Arvinas Reports Positive Phase 1 Data for ARV-102
23h ago
8K
ARVN
Arvinas presents data from Phase 1 clinical trial of ARV-102
PremiumThe Fly
Arvinas presents data from Phase 1 clinical trial of ARV-102
24h ago
ARVN
Arvinas price target raised to $18 from $15 at Citi
PremiumThe FlyArvinas price target raised to $18 from $15 at Citi
14d ago
ARVN
Regulatory Turbulence: How FDA Disruptions and Budget Cuts Threaten Arvinas Holding Company’s Drug Development Timelines
Premium
Company Announcements
Regulatory Turbulence: How FDA Disruptions and Budget Cuts Threaten Arvinas Holding Company’s Drug Development Timelines
21d ago
ARVN
Arvinas price target raised to $11 from $9 at Wedbush
Premium
The Fly
Arvinas price target raised to $11 from $9 at Wedbush
22d ago
ARVN
Arvinas price target raised to $19 from $14 at Evercore ISI
PremiumThe Fly
Arvinas price target raised to $19 from $14 at Evercore ISI
22d ago
ARVN
Arvinas price target raised to $20 from $16 at Piper Sandler
PremiumThe Fly
Arvinas price target raised to $20 from $16 at Piper Sandler
22d ago
ARVN
Arvinas: Strong Pipeline Momentum, De-Risked Cash Runway, and Attractive Risk‑Reward Support Buy Rating
PremiumRatings
Arvinas: Strong Pipeline Momentum, De-Risked Cash Runway, and Attractive Risk‑Reward Support Buy Rating
22d ago
ARVN
Arvinas Earnings Call: High Science, Tight Cash
PremiumCompany Announcements
Arvinas Earnings Call: High Science, Tight Cash
22d ago
ARVN
Balancing Emerging Clinical Momentum and Commercial Uncertainty: Maintaining a Hold on Arvinas Ahead of Key 2026 Readouts
PremiumRatingsBalancing Emerging Clinical Momentum and Commercial Uncertainty: Maintaining a Hold on Arvinas Ahead of Key 2026 Readouts
23d ago
ARVN
Arvinas price target raised to $11 from $9 at Wedbush
Premium
The Fly
Arvinas price target raised to $11 from $9 at Wedbush
23d ago
ARVN
Arvinas sees cash runway into 2H28
Premium
The Fly
Arvinas sees cash runway into 2H28
23d ago
ARVN
Arvinas reports Q4 EPS ($1.10), consensus (57c)
PremiumThe Fly
Arvinas reports Q4 EPS ($1.10), consensus (57c)
23d ago
ARVN
Arvinas reports Q3 EPS ($1.10), consensus (57c)
PremiumThe Fly
Arvinas reports Q3 EPS ($1.10), consensus (57c)
23d ago
ARVN
ARVN Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
ARVN Upcoming Earnings Report: What to Expect?
25d ago
ARVN
Arvinas Announces Leadership Transition and New CEO Appointment
PremiumCompany Announcements
Arvinas Announces Leadership Transition and New CEO Appointment
1M ago
8K
ARVN
Arvinas appoints Randy Teel as President, CEO, director
PremiumThe FlyArvinas appoints Randy Teel as President, CEO, director
1M ago
ARVN
Private Markets: SpaceX interviews banks to lead IPO, Skild AI raises $1.4B
Premium
The Fly
Private Markets: SpaceX interviews banks to lead IPO, Skild AI raises $1.4B
2M ago
V
MA
Arvinas upgraded to Buy from Neutral at Citi
Premium
The Fly
Arvinas upgraded to Buy from Neutral at Citi
2M ago
ARVN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >